blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3288583

EP3288583 - NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  16.07.2021
Database last updated on 24.08.2024
FormerExamination is in progress
Status updated on  11.01.2019
FormerRequest for examination was made
Status updated on  02.02.2018
FormerThe international publication has been made
Status updated on  04.11.2016
Most recent event   Tooltip16.07.2021Application deemed to be withdrawnpublished on 18.08.2021  [2021/33]
Applicant(s)For all designated states
Autolus Limited
Forest House
58 Wood Lane
London W12 7RZ / GB
[2021/04]
Former [2019/52]For all designated states
UCL Business Ltd
The Network Building
97 Tottenham Court Road
London W1T 4TP / GB
Former [2018/10]For all designated states
UCL Business PLC
The Network Building 97 Tottenham Court Road
London W1T 4TP / GB
Inventor(s)01 / PULÉ, Martin
c/o Autolus Ltd
Forest House
Depot Road
London W12 7RP / GB
02 / CORDOBA, Shaun
c/o Autolus Ltd
Forest House
Depot Road
London W12 7RP / GB
 [2018/10]
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Former [2018/10]D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Application number, filing date16721212.526.04.2016
[2018/10]
WO2016GB51163
Priority number, dateGB2015000711927.04.2015         Original published format: GB 201507119
[2018/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016174407
Date:03.11.2016
Language:EN
[2016/44]
Type: A1 Application with search report 
No.:EP3288583
Date:07.03.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 03.11.2016 takes the place of the publication of the European patent application.
[2018/10]
Search report(s)International search report - published on:EP03.11.2016
ClassificationIPC:A61K39/00, C07K14/705, C07K16/28, C07K19/00
[2018/10]
CPC:
C07K16/2803 (EP,US); A61K35/17 (US); A61K39/0011 (US);
A61K39/461 (EP); A61K39/4631 (EP); A61K39/464404 (EP);
A61K39/464411 (EP); A61K39/464412 (EP); A61K39/464471 (EP);
A61P35/00 (EP,US); C07K14/70503 (US); C07K14/7051 (EP,US);
C07K14/70517 (US); C07K14/70521 (US); C07K16/2863 (EP,US);
C07K16/3084 (EP,US); C12N7/00 (US); C12N9/16 (EP,US);
C12Y301/03048 (EP,US); A61K2039/5156 (US); A61K2239/28 (EP);
C07K2317/622 (EP,US); C07K2319/02 (EP,US); C07K2319/03 (US);
C07K2319/033 (EP,US); C07K2319/04 (US); C07K2319/05 (US);
C12N2710/10333 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/10]
TitleGerman:NUKLEINSÄUREKONSTRUKT ZUR EXPRESSION VON MEHR ALS EINEM CHIMÄREN ANTIGENREZEPTOR[2018/10]
English:NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR[2018/10]
French:STRUCTURE D'ACIDE NUCLÉIQUE POUR EXPRIMER PLUS D'UN RÉCEPTEUR D'ANTIGÈNE CHIMÈRE[2018/10]
Entry into regional phase27.11.2017National basic fee paid 
27.11.2017Designation fee(s) paid 
27.11.2017Examination fee paid 
Examination procedure30.10.2017Date on which the examining division has become responsible
27.11.2017Examination requested  [2018/10]
13.06.2018Amendment by applicant (claims and/or description)
10.01.2019Despatch of a communication from the examining division (Time limit: M04)
29.04.2019Reply to a communication from the examining division
05.09.2019Despatch of a communication from the examining division (Time limit: M06)
13.03.2020Reply to a communication from the examining division
10.09.2020Despatch of a communication from the examining division (Time limit: M06)
23.03.2021Application deemed to be withdrawn, date of legal effect  [2021/33]
14.04.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2021/33]
Fees paidRenewal fee
26.04.2018Renewal fee patent year 03
29.04.2019Renewal fee patent year 04
27.04.2020Renewal fee patent year 05
27.04.2021Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO2013063419  (UNIV PENNSYLVANIA [US], et al) [Y] 1-39 * see pages 10-11, 21-26, 31-34 and claims 1-9 and 12-14 *;
 [Y]WO2013154760  (US HEALTH [US]) [Y] 1-39 * see pages 3-12 *;
 [Y]WO2014127261  (UNIV CALIFORNIA [US]) [Y] 1-39 * see pages 8-22 and claims 1-9 *;
 [Y]WO2014145252  (MILONE MICHAEL C [US], et al) [Y] 1-39 * the whole document *;
 [Y]WO2015052536  (UCL BUSINESS PLC [GB]) [Y] 1-39 * the whole document *;
 [IP]WO2015075470  (UCL BUSINESS PLC [GB]) [IP] 1-39 * the whole document *;
 [E]WO2016102965  (UCL BUSINESS PLC [GB], et al) [E] 1-39* the whole document *;
 [XY]  - ZAKARIA GRADA ET AL, "TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy", MOLECULAR THERAPY-NUCLEIC ACIDS, (20130701), vol. 2, no. 7, doi:10.1038/mtna.2013.32, page e105, XP055152438 [X] 1-4,28-30,32 * the whole document * [Y] 1-39

DOI:   http://dx.doi.org/10.1038/mtna.2013.32
 [Y]  - V. D. FEDOROV ET AL, "PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses", SCIENCE TRANSLATIONAL MEDICINE, (20131211), vol. 5, no. 215, doi:10.1126/scitranslmed.3006597, ISSN 1946-6234, pages 215ra172 - 215ra172, XP055210508 [Y] 1-39 * the whole document *

DOI:   http://dx.doi.org/10.1126/scitranslmed.3006597
 [Y]  - SHAUN CORDOBA ET AL, "Chimeric Antigen Receptor Logical AND Gate Based on CD45/CD148 Phosphatases", MOLECULAR THERAPY, (20140501), vol. 22, no. Suppl. 1, ISSN 1525-0016, page S59, XP055170616 [Y] 1-39 * the whole document *
 [Y]  - MICHAEL C JENSEN ET AL, "Designing chimeric antigen receptors to effectively and safely target tumors", CURRENT OPINION IN IMMUNOLOGY, (20150123), vol. 33, doi:10.1016/j.coi.2015.01.002, ISSN 0952-7915, pages 9 - 15, XP055217152 [Y] 1-39 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.coi.2015.01.002
 [Y]  - M. SADELAIN ET AL, "The Basic Principles of Chimeric Antigen Receptor Design", CANCER DISCOVERY, US, (20130401), vol. 3, no. 4, doi:10.1158/2159-8290.CD-12-0548, ISSN 2159-8274, pages 388 - 398, XP055287277 [Y] 1-39 * the whole document *

DOI:   http://dx.doi.org/10.1158/2159-8290.CD-12-0548
 [Y]  - M. SHARPE ET AL, "Genetically modified T cells in cancer therapy: opportunities and challenges", DISEASE MODELS & MECHANISMS, GB, (20150401), vol. 8, no. 4, doi:10.1242/dmm.018036, ISSN 1754-8403, pages 337 - 350, XP055288112 [Y] 1-39 * the whole document *

DOI:   http://dx.doi.org/10.1242/dmm.018036
by applicantWO0063372
 US7052906
 WO2013153391
    - LAMERS ET AL., MOL. THER., (2013), vol. 21, pages 904 - 912
    - STAUB ET AL., CELL. SIGNAL., (2004), vol. 16, pages 435 - 456
    - DONNELLY ET AL., J. GEN. VIROL., (2001), vol. 82, pages 1027 - 1041
    - BONIFACINO; TRAUB, ANN. REV. BIOCHEM., (2003), vol. 72, pages 395 - 447
    - BRAULKE; BONIFACINO, BIOCHIMICA AND BIOPHYSICA ACTA, (2009), vol. 1793, pages 605 - 614
    - GRIFFITH, CURRENT BIOLOGY, (2001), vol. 11, pages R226 - R228
    - MELLMAN; NELSON, NAT REV MOL CELL BIOL., (2008), vol. 9, pages 833 - 845
    - DELL'ANGELICA; PAYNE, CELL, (2001), vol. 106, pages 395 - 398
    - SCHAFER ET AL., EMBO J., (1995), vol. 14, pages 2424 - 2435
    - TREJO, MOL. PHARMACOL., (2005), vol. 67, pages 1388 - 1390
    - PELHAM, METH. ENZYMOL., (2000), vol. 327, pages 279 - 283
    - GODER; SPIESS, FEBS LETT, (2001), vol. 504, pages 87 - 93
    - BONIFACINO; TRAUB, ANNU. REV. BIOCHEM., (2003), vol. 72, pages 395 - 447
    - SCHEEL ET AL., J. BIOL. CHEM., (1993), vol. 268, page 7465
    - TEASDALE; JACKSON, ANNU. REV. CELL DEV. BIOL., (1996), vol. 12, page 27
 WO2014GB53452
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.